MedTrace Logo

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

NCT01687764 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-09-19

No results posted yet for this study

Summary

The objective of this project is to test the combination of active or placebo Attentional Bias Modification Treatment (ABMT) to either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for anxiety disorders in children.

Conditions

Interventions

OTHER

Attentional Bias Modification Treatment (ABMT) - Active

The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.

OTHER

Attentional Bias Modification Treatment - Placebo

The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.

BEHAVIORAL

Cognitive Behavioral Group Therapy

"FRIENDS for Life" Australian protocol for the treatment of anxiety disorders in children

BEHAVIORAL

Psychoeducational Control Intervention

Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Gisele G Manfro, MD, PhD · Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre

  • Silvia H Koller, PhD · Federal University of Rio Grande do Sul / University of Psychology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
7 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States
  • Australia
  • Brazil
  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01687764 on ClinicalTrials.gov